← Eichor
Study identifier: NCT07214688 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies

Condition: Allogeneic Stem Cell Transplant Recipient  ·  Sponsor: Hackensack Meridian Health

PhasePhase 2
Planned participants209
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide (PTCy) (experimental regimen) improves the 1-year survival of allogeneic stem cell transplant recipients.

This description comes directly from the study's public registry record.

Talk to the study team

Oncology Clinical Research Referral Office  ·  551-996-1777  ·  OncologyResearchReferral@hmhn.org

Always discuss trial participation with your own doctor first.

Locations (3)

Lombardi Comprehensive Cancer Center at Georgetown University Medical CenterWashington D.C., District of Columbia, United StatesNot Yet Recruiting
John Theurer Cancer Center at Hackensack University Medical CenterHackensack, New Jersey, United StatesRecruiting
John Theurer Cancer Center at Jersey Shore University Medical CenterNeptune City, New Jersey, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07214688